I
nfections have long been known to complicate care in patients after traumatic injury frequently leading to excess morbidity and mortality. 1, 2 In no setting is this more well recognized than the challenging environment of combat casualty care. During the current military conflicts in Iraq and Afghanistan, Operations Iraqi and Enduring Freedom (OIF/OEF), major advances resulting in increased survival among wounded personnel have been observed. These include enhanced training of medics, forward deployment of surgical assets, rapid medical evacuation, and improvements in body armor. [3] [4] [5] The significant advances leading to survival are coupled with major challenges in care due to the extensive nature of the injuries, profound bone and soft tissue disruption, and extensive wound contamination. 6, 7 In addition, the rapid transit of these patients through multiple echelons of medical care places significant obstacles on infection control in an era of increasing risk due to hospital-associated multidrug resistant organisms (MDRO). 8, 9 The U.S. Department of Defense (DoD) has implemented a range of measures to improve combat casualty care and mitigate risk of infectious complications. A Joint Theater Trauma System and Joint Theater Trauma Registry (JTTR) have been developed to benchmark metrics and to provide a timely assessment of performance improvement interventions. 5, 10, 11 Efforts to prevent infection include the development of guidelines for the prevention of infection related to combat injuries through comprehensive review of current evidence and consensus review by military and civilian experts in trauma, infectious disease, infection control, preventive medicine, and surgical specialties. 12 In addition, standardized infection control measures across echelons of care accompanied by enhanced MDRO surveillance and serial evaluation have also been implemented. 13, 14 Despite the growing literature describing infectious complications of combat-related trauma, there is still a lack of prospectively collected standardized infection data that include specific therapy, microbiological findings, and clinical outcomes across treatment facilities. This report describes the initial data and current status of an ongoing 5-year prospective observational cohort study of infectious complications associated with traumatic injury sustained during deployment, the DoD-Department of Veterans Affairs (VA) Trauma Infectious Disease Outcomes Study (TIDOS).
PATIENTS AND METHODS

TIDOS Project Design
The TIDOS project is an observational cohort study of short-and long-term infectious disease outcomes after a deployment-related traumatic injury. TIDOS cohort eligibility criteria include the following: active duty personnel or DoD beneficiary, aged Ն18 years, wounded or injured during deployment requiring return via Level IV at Landstuhl Regional Medical Center, Landstuhl, Germany, to a participating DoD hospital in the United States, and providing informed consent or surrogate consent through a legally authorized representative. Participating Level V clinical sites include the National Naval Medical Center, Bethesda, MD, Brooke Army Medical Center, San Antonio, TX, and Walter Reed Army Medical Center, Washington, DC. Consenting patients are enrolled in the study before discharge from one of the participating Level V hospitals. Participants are contacted periodically at 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months and then yearly for 5 years after discharge. Follow-up methods include subject interviews, web-based questionnaires, and query of DoD and Department of Veterans Affairs electronic healthcare databases.
Patient trauma history, injury severity scoring, and surgical management is obtained through selected data elements retrieved from the DoD JTTR. 5 The JTTR was established by the Assistant Secretary of Defense for Health Affairs as a means to provide an effective performance improvement tool to assess combat casualty care epidemiology, treatment, and outcome. An infectious diseases (ID) module to augment the JTTR was developed to capture infection-specific data throughout levels of care at participating hospitals. This ID-specific information includes diagnoses, treatments, and outcomes of bloodstream infections (BSI), clinical sepsis, bone and joint infections, skin and soft tissue infections (SSTI), central nervous system (CNS) infections, intrathoracic/pulmonary infections, and intra-abdominal infection. The JTTR/ID module captures data on all active duty military trauma patients admitted to Level IV and selected Level V facilities. A comprehensive assessment of the overall population and the representativeness of the TIDOS cohort were performed by analyzing de-identified JTTR/ID module data from nonenrolled trauma patients admitted through Level IV during the period. The study is approved by the institutional review boards of the Uniformed Services University of the Health Sciences and the St. Louis Veterans Administration Medical Center.
This report includes subjects admitted to Level IV during the first 3 months of the study (June 1 to August 31, 2009) along with subject experience through Level V hospitalization (for those admitted to participating Level V sites) and up to 6 months of follow-up post Level V discharge (for those consenting to follow-up).
Study Definitions/Endpoints
Trauma care within the military is typically described based on levels defined as follows: Level I, point of injury/first responder care within the combat zone; Level II, resuscitation and surgical stabilization at medical units (not hospitals) within the combat zone (which may be augmented with surgical assets); Level III, medical/surgical care at combat support or other theater hospitals (highest available care in the combat zone); Level IV, regional medical center care located in communication zone (e.g., Landstuhl Regional Medical Center), and Level V, definitive treatment/rehabilitation at major tertiary care medical centers in United States.
Injury parameters include type of injury (blunt or penetrating), mechanism of injury, anatomic site, early interventions, and delayed care management. Severity scoring systems are used to provide internal and external comparability of this traumatized patient population both for initial assessment of the traumatic injury and subsequent interval health assessments. The Injury Severity Score (ISS) uses anatomic classification for injury classification and severity scoring. 15 Interval assessments of general health are undertaken using the Sequential Organ Failure Assessment (SOFA). 16 The SOFA score is composed of scores from six organ systems, graded from 0 to 4 according to the degree of dysfunction/failure.
Infectious disease events are classified using a combination of clinical findings, laboratory and other test results, as shown in Table 1 , available through medical record review, applying standardized definitions for nosocomial infections used by the National Healthcare Safety Network. 17 In addition, a physician's clinical diagnosis in the absence of meeting a priori defined criteria was also counted as an ID event provided there was initiation of directed antimicrobial therapy with continuation of this therapy for Ն5 days. An ID event is excluded if the medical record states an alternative diagnosis is determined accompanied by discontinuation of directed antimicrobial therapy.
Clinical Microbiology
Microbiological evaluations to diagnose infections are performed at the discretion of the clinical providers. Infection control policy dictates the timing and methods for active surveillance for colonization. Targeted surveillance includes admission swabs of the groin and axilla (axillary swabs discontinued during the period reported) and external nares culture and/or PCR to detect methicillin resistant S. aureus (MRSA). Antibiotic susceptibility results, performed by each hospital's clinical microbiology laboratory, are interpreted in accordance with Clinical and Laboratory Standards Institute (CLSI) if available. MDRO classification is defined as any bacteria resistant to Ն3 classes of antibiotics (aminoglycosides, ␤-lactams, carbapenems, and fluoroquinolones), presence of extended spectrum ␤-lactamase (ESBL), or Klebsiella pneumoniae carbapenemase (KPC) production, MRSA, or vancomycin-resistant Enterococcus (VRE). 18 After completion of identification and susceptibility testing at the clinical microbiology laboratory (per standard procedures at each site), research staff collect bacterial and fungal isolates for archival for future phenotypic and genotypic analysis. All participating sites use either BD Phoenix (BD Biosciences, Sparks, MD) or Vitek 2 (bioMérieux Inc., Hazelwood, MO) automated systems for speciation and antibiotic susceptibility testing along with standardized resistance testing through disc Superficial: Involves only skin/subcutaneous tissue and Ն1 of the following from each area: (1) Pain/tenderness, localized swelling, redness, or heat AND 2) purulent site drainage, organisms isolated from aspirate/aseptically obtained culture of fluid/tissue, organisms isolated from purulent drainage, or visual evidence of superficial incisional SSI or SSTI. Deep: Ն1 of the following: purulent site drainage, organisms isolated from aspirate/aseptically obtained culture of fluid/tissue, organisms isolated from purulent drainage, deep wound/incision spontaneously dehisces or is deliberately opened by a surgeon in the presence of fever or localized tenderness, unless the wound culture is negative, abscess or other evidence of infection.
Central nervous system infection
Intracranial infection: ͓brain abscess, subdural or epidural infection, encephalitis͔ or ͓positive culture from brain tissue or dura͔ or ͓abscess/evidence of intracranial infection seen during surgical procedure or histopathology͔ or ͓patient has at least one of the following from each group: (headache, dizziness, fever, localizing neurological signs, or change in level of consciousness or confusion) or (organisms seen on microscopy of brain/abscess tissue obtained by needle aspiration/biopsy or radiographic evidence of infection)͔. Meningitis or ventriculitis: Positive CSF culture or Ն1 of the following from each area: (fever, headache, stiff neck, meningeal signs, cranial nerve signs, or irritability) and (increased white cells, elevated protein, and/or decreased glucose in CSF, positive CSF Gram stain, positive blood culture, positive CSF, blood, or urine antigen test). Spinal abscess without meningitis: positive culture from abscess in the spinal epidural/subdural space or abscess in the spinal epidural/subdural space seen during surgery or Ն1 of the following from each area: (fever, back pain, focal tenderness, radiculitis, paraparesis, or paraplegia) and (positive blood culture or radiographic evidence). Intrathoracic/pulmonary infection Pneumonia: both must be present-(New or progressive infiltrate seen on radiology film and evidence of infection (Temp Ͼ38°C or Ͻ36°C or WBC Ն12,000 or Ͻ4,000) and (new onset purulent sputum, change in character of sputum, increase respiratory secretions, new onset worsening cough, dyspnea, or tachypnea, rales/bronchial breath sounds, worsening gas exchange, same organism growing from respiratory secretions as found in blood cultures, positive culture from minimally contaminated lower respiratory tract specimen, Ն5% BAL-obtained cells contain intracellular bacteria on direct microscopy, or laboratory evidence of uncommon pathogen). Empyema: Ն1 of the following: positive culture from pleural fluid/pleural fluid biochemical analysis consistent with empyema, empyema seen during surgery or histopathology, or radiographic evidence consistent with empyema. Lung abscess: Ն1 of the following: organism seen on smear or cultured from lung tissue or fluid, including pleural fluid, lung abscess seen during a surgical operation or histopathology, or abscess cavity seen on radiographic examination of lung. Intraabdominal infection Includes gall bladder, bile ducts, liver, spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not otherwise specified; positive culture of purulent material from intra-abdominal space obtained during surgery/needle aspiration or abscess or other evidence of intraabdominal infection seen during surgery/histopathology exam or Ն2 of the following: temp Ͼ38°C, nausea, vomiting, abdominal pain, jaundice, or paraparesis ϩ or Ն1 of the following: organisms cultured from drainage from surgically placed drain, organisms seen on Gram stain of drainage/tissue obtained during surgery or needle aspiration, or radiographic evidence of infect.
* Diagnostic criteria derived from standardized definitions for nosocomial infections used by the National Healthcare Safety Network (NHSN). 17 The 
Statistical Analysis
Statistical analyses include descriptive statistics shown as counts (percentages) for categorical variables, and medians (interquartile ranges) for continuous variables. Group comparisons were conducted using Fisher's exact test and the Wilcoxon Mann-Whitney U test of no difference between groups for the categorical and continuous variables, respectively. Odds ratios and confidence intervals were computed using a method recently proposed by Fay. 19 Continuous variables with skewed distribution were compared using the exact Wilcoxon test. 20 ID events are classified as described above with the following additional steps to assure each event is unique and to prevent overestimation: (1) patients with ID events of the same syndromic type were verified to have occurred Ն1 month apart and not represent a continuation of the initial event; (2) patients with multiple ID events classified as either SSTI or osteomyelitis were verified to be from different anatomic regions; and (3) SSTI and osteomyelitis ID events occurring at the same anatomic location with date of diagnosis Ϯ3 days were coded as a single ID event for rate calculation (however, both syndrome types are recorded). ID events occurring within the same level of care were individually reviewed by the principal investigator for confirmation. Incidence density rates were calculated by number of ID events from time of trauma through discharge at last hospital facility during initial inpatient period (Level IV or V) with exact Poisson confidence intervals. All analyses were conducted using R version 2.11 (R foundation; www.r-project.org) and SAS version 9.2 (SAS Corporation, Cary, NC).
RESULTS
TIDOS Enrollment
Cohort enrollment and data collection began June 2009. The patient flow is outlined in Figure 1 from the operational theater, admission at Level IV care, Level IV discharge disposition, distribution across participating U.S. military hospitals, and subsequent enrollment, follow-up, and VA registration for the TIDOS cohort. During this period, there were 356 (ϳ65% in support of OEF) Level IV trauma admissions with 192 (53.9%) of these patients transferred to participating U.S. military hospitals, most commonly to the Walter Reed Army Medical Center with 99 patients (51.5%). TIDOS cohort enrollment of potentially eligible patients is at 54% with ϳ30% to 40% of the patients not contacted to discuss enrollment frequently due to short inpatient stays and/or weekend discharges. A relatively high proportion of the TIDOS cohort (40%) have left active duty service and registered for care in the Veterans Administration Medical Center system in less than 1 year since date of injury.
Overall Population Comparison With TIDOS Cohort
As detailed on Table 2 , there were no significant differences between operational theater, gender, or age when comparing patient characteristics either by participating versus non-participating U.S. hospitals or by TIDOS enrollment status. The distribution by branch of service among enrolled versus non-enrolled patients showed a higher proportion of Army (OR, 2.2, 95% CI, 1.1-4.2) and lower Marine Corps (OR, 0.3, 95% CI, 0.2-0.7) service among the cohort. The mechanism of trauma was less likely to be caused by an explosive device in the patients transferred to the nonparticipating hospitals. This group of patients also had a higher proportion of injuries caused by gunshot wounds (OR, 2.5; 95% CI, 1.3-4.5). The group with the highest ISS was the TIDOS enrolled cohort (p Ͻ 0.0001).
The median (interquartile ranges) time (in days) from trauma to Level IV admission was similar irrespective of eventual Level IV disposition: return to duty 3.0 (1-6), non-participating Level V 3.0 (2-4) and participating Level V 3.0 (2-4). As expected the median hospitalization at Level IV was significantly less than at the U.S. hospitals, 2 compared with 15 days (Table 3 ). The TIDOS enrolled group had longer hospitalizations than non-enrolled patients, 17 days versus 10 days. The patients transferred to participating U.S. hospitals had significantly higher rates of ICU admissions, mechanical ventilation, proportion with massive blood transfusion requirement, admission SOFA scores, and use of other invasive interventions while at Level IV compared with patients transferred to nonparticipating hospitals. There was however no significant differences in these rates between TIDOS enrolled versus non-enrolled patients. Of the 123 Level IV ICU admits, 94 (76.4%) were transferred to a participating U.S. hospital. At discharge from participating U.S. hospitals, there was no statistical difference, based on TIDOS enrollment, for the numbers of patients with indwelling orthopedic hardware, intravascular lines, or ongoing antimicrobial therapy.
Infectious Disease Events During Initial Hospitalization (Level IV and V)
The proportion of patients experiencing Ն1 ID event increased from 5.1% at Level IV to 26.6% at Level V ( Table  4) . The number of patients experiencing infection at Level IV by discharge disposition is as follows: patients returning to duty, 3 (16.7%); transferring to non-participating Level V facility, 0 (0.0%); participating Level V without TIDOS enrollment, 8 (9.1%); and participating Level V with enrollment, 7 (6.7%). A total of 117 unique ID events were documented at Level IV and V (Table 5) ; 95 (81.2%) by meeting a priori criteria and 22 (18.8%) by infection suspicion (not meeting criteria) plus treated with Ն5 days directed antimicrobial therapy. There was no statistical difference between the proportions classified as ID events meeting criteria at Level IV versus Level V, 71.4% versus 83.3%, respectively. The specific ID event type along with the relative percentage (in descending order) and the number of patients affected for all of The most common ID syndrome observed at Level IV was pneumonia in 10.6% of the ICU admissions (none in the patients admitted to the ward). The more common syndromes in the U.S. hospitals were wound infections (SSTI) at 17.7%, BSI at 8.9%, and osteomyelitis at 8.9%. The infection incidence rate combined across both Level IV and V care (Table  5 ) was approximately 3.5-fold higher for those patients stratified based on the site of initial admission at level 4 (ICU or ward). Among the infections observed during the inpatient period, 19 (14.3%) required ongoing treatment at discharge.
Clinical Microbiology Findings
Hospital-based active colonization surveillance at Level IV documented 75 of 302 patients screened (24.8%) to have positive cultures and of those 15 (20.0%) yielded a MDRO. At U.S. hospitals, 77 of 192 patients screened (40.1%) were found to have positive cultures and of those, 29 (37.7%) yielded a MDRO. For all patients screened, the proportion found to have a MDRO was higher at U.S. hospitals compared with Level IV, 15.1 versus 4.9%, respectively. The most common bacteria observed were E. coli (ESBL) producers as shown in Table 6 . A total of 117 unique ID events were documented among 62 patients. Of these, 89 (76.1%) had Ն1 positive microbiological isolate for a total of 172 distinct microorganisms. Coagulase-negative Staphylococcus, most commonly S. epidermidis, was the most common clinical isolate, typically associated with BSI. E. coli infections, frequently in BSI and wound infections were * A patient was followed up through the last hospital discharge captured at which point the data was censored. For patients admitted to participating Level 5 hospitals, this includes the entire inpatient Level 5 period; whereas, patients not transferred to a participating Level 5 hospital were censored at the time of the Level 4 discharge.
† ID events met either predefined criteria (n ϭ 95; 81.2%) or infection suspicion (not meeting criteria) plus Ն5 d directed antimicrobial therapy (n ϭ 22; 18.8%). † Colonization based on infection control hospital policy for active screening for colonization ͓most commonly entails a groin swab (Level IV and V) combined with external nares swab for MRSA culture and/or MRSA PCR (Level V only)͔.
‡ A total of 117 unique ID events were documented among 62 patients. Of these, 89 (76.1%) unique ID events had had Ն1 positive microbiological isolate for a total of 172 distinct microorganisms. 
Posthospitalization Follow-Up
During the follow-up period to date, a total of 28 incident infections meeting criteria were observed with the following distribution: sepsis (without focal infection), 1; BSI, 2; wound/SSTI, 13; osteomyelitis, 5; pneumonia, 1; and miscellaneous, 6 (3 with sinusitis, 2 with urinary tract infections, and 1 with C. difficile infection). A total of 18 of the 81 patients (22.2%), having at least one follow-up assessment, were documented to have an incident infection after the initial U.S hospitalization.
DISCUSSION
As of July 23, 2010, there have been 13,978 and 3,812 U.S. service members wounded in action and not returned to duty within 72 hours in support of Operation Iraqi Freedom and Operation Enduring Freedom (Afghanistan), respectively, since the beginning of combat operations. 21 These conflicts have witnessed dramatic improvements in combat casualty care and patient survival. 5, 10, 11 Concurrently, reports of multidrug-resistant infections present challenges to infection control and clinical management, 13 as these patients transit multiple diverse levels of care including forward surgical hospitals, during aeromedical evacuations, Landstuhl Regional Medical Center, tertiary care centers in the United States, and frequently into the Veterans Administration health care system. 22, 23 The complex nature of polytrauma in many of these cases 6 and 7 complicates care increasing the risk of infections at individual hospitals caring for these patients. Research efforts 8, 24, 25 coupled with policy guidance 13 have led to better understanding and greater system-based standardization of practices directed at the nosocomial reservoir for these MDR infections. The TIDOS project is the first prospective evaluation of infectious disease complications and subsequent outcomes using predefined standardized methodology combined with analysis of clinical management, surgical and medical care (i.e., antimicrobial therapy), and clinical microbiology results across levels of care, medical facilities, and outpatient follow-up. This initial report provides quantitative estimates for incident infections among these trauma patients in the first 3-month period of the project, highlighting the common occurrence of these complications particularly as the patients move to higher levels of care (5.1% at Level IV vs. 26.6% at Level V), and the common occurrence of incident infections posthospitalizations (22% of patients).
The wounding patterns in modern warfare 26 and specifically in the current conflicts have been well described. 27 The predominance of severe extremity injury, often related to blast injuries from explosive devices, with extensive soft tissue and bone loss, places these patients at significant risk of complicated soft tissue infections and osteomyelitis. On average, as seen in these data, certain infections arise later (wound/SSTI and osteomyelitis ϳ12-15 days) as compared with pneumonia (ϳ3 days) which may lend further insight into understanding potential reservoirs of infection and possible implications for approaches to prevent late-onset infections. In addition, many of these infections require ongoing management at discharge (ϳ15%) further impacting patient quality of life. In this early report of the project, incident infections in 22% of patients, most commonly soft tissue infections and osteomyelitis, documented after initial U.S. hospitalization highlight the necessity to actively survey for these late-onset outcomes and evaluate risk factors. Previous research has identified factors related to the characteristics of trauma and the early indicators of severity that provide predictive value for estimating infectious complications. 4, 15, 28, 29 Trauma-specific factors previously reported to increase infection risk include, but are not limited to, requirement for massive blood transfusion, 28 28 open, grossly contaminated comminuted fractures, 6 and retained orthopedic hardware/invasive medical devices. Ascertainment of risks and assessment of various treatment strategies should be assessed in the context of both short-and long-term complications particularly in an era of increasing exposure to MDRO in healthcare environments. For example, reports have documented increases in infection rates among a cohort of patients with tibial fractures managed with tibial nailing as the period of observation was increased, as would be expected given the subacute nature of many of these infections. 7 A recent report demonstrates encouraging findings supportive of temporary external fixation of type III tibia fractures without late onset of infectious complication in a 2-year follow-up period at one treatment facility. 31 This report highlights analyses that could be replicated across military facilities through the TIDOS data. Future analyses of TIDOS data, particularly extending evaluations into the VA healthcare system, will assist in informing best practices.
This report provides a cross-sectional view of a period of time in the summer and early fall of 2009. During this timeframe, there were notable occurrences external to the project impacting the findings. Of most importance, the spring of 2009 saw the shift, which continues to date, of much higher proportion of casualties occurring in Afghanistan than Iraq, 65.4% of overall patients wounded in support of OEF. The mechanism of injury and wounding patterns seen in these patients do not differ from previous reports where most injuries occurred in Iraq. In regards to infection risk and clinical management, recent Department of Defense efforts in 2008/2009 to promote standardization of practice patterns for infection control in theater and guidance for surgical and antimicrobial therapy for infection prevention have been promulgated. 12 It is expected that these efforts have contributed to a reduction in infection rates; however, because there is no similarly well-characterized data to compare against this is uncertain. Previous efforts to estimate infection rates have included analysis of the JTTR using captured data on International Classification of Diseases (ICD-9) codes. 32 This report covered a period from 2003 to 2006, although the lack of complete records restricted the analysis and almost all patients had been injured in Iraq. In this analysis, approximately one-third of the patients were found to have an ICD-9 code, indicating an infectious complication, most commonly involving wound followed by lung infections, with gramnegative bacteria, when a pathogen was reported, accounting for 47% of reports. The lack of additional clinical information for these codes or verification of fulfilling predefined criteria makes direct comparison with data reported in this analysis difficult. The observed cumulative infection incidence of 26.6% for patients followed through Level 5 care approximates what has been previously reported. Increase in incident infections as patients move across echelons of care is also consistent with the higher rates of infection that have been reported in single center studies in the United States or among British military. 23, 33, 34 The predominance of gram-negative infections reported in this study is also consistent with previous observations. 23 Notably, the lower rates of Acinetobacter calcoaceticus-baumannii complex infections, frequently MDR, compared with previous reports of high rates of colonization 25 and infection 22 may be related to increased infection control vigilance although this is not certain. High levels of other multidrug-resistant organisms observed in this report, primarily E. coli (ESBL) producers, detected through active surveillance for colonization and in clinical isolates emphasize the need for ongoing surveillance and development of improved measures for prevention and clinical management.
To generalize the TIDOS findings and provide the correct context to other military or civilian trauma populations, it is necessary to compare the cohort to the overall population of patients who are admitted through Level IV after traumatic injury. There are branch points along the path before the first opportunity to enroll a patient in the TIDOS cohort that restrict broad sampling of the overall trauma patient population. TIDOS enrollment occurs before discharge from an U.S. military hospital, which is the first feasible time to interact with a large proportion of these severely traumatized patients and/or their families. As evident through these data, patients returning to duty and patients transferred to U.S. military hospitals not participating in the TIDOS project differ significantly (i.e., less severe injury and lower levels of interventions suggestive of patients requiring less intense care), from patients transferred to a participating site. This is not surprising because the participating sites are centers with unique expertise in surgical subspecialty or burn center care and are expected to receive the most seriously injured patients. At a participating site, the opportunity to interact with a patient or their family may be limited by a very brief inpatient stay if the patient is quickly moved to ambulatory management or, on the other extreme, a seriously injured patient where potential to interact with family members may be restricted or deemed not appropriate. On review of the data, the TIDOS cohort population appears to be have more extensive injury, and a more complicated and prolonged hospital course. In addition, the high rate of Veterans Administration registration (40%) among the cohort participants at only 1 year further supports the data that this sample represent, in general, a more severely injured subset who are likely at higher risk for infectious complications. As the study continues to enroll, now exceeding 725 participants, it is expected that the cohort will provide adequate representation of the population permitting generalization to broader military and civilian trauma patient populations; however, most important it will include substantial numbers of patients experiencing complex combat trauma for analysis which are otherwise not available in the civilian trauma literature.
Limitations of the study include the dependence on medical record review, which at times has variable quality on documentation of symptoms, signs, or additional findings that comprise criteria required in determining whether an infectious disease event meets prospectively defined criteria. Medical record review, akin to similar approaches used in hospital-based infection control practice, is however a major advance over limited information available through ICD-9 coded data. Despite this inherent limitation, the TIDOS project provides the most comprehensive assessment of infectious complications after traumatic injury to date within the Department of Defense and emphasizes the significant impact infectious complications have on wounded military personnel. The successful project initiation, along with the JTTR supplemental ID module, will provide unique insights into short-and long-term infectious complications of combat trauma to develop future strategies for improving prevention and treatment of infections.
